FDA Approved: INLURIYO — Original Application (Eli Lilly and Company)

View source ↗

Summary

FDA approved INLURIYO (imlunestrant) from Eli Lilly in an original NDA, an oral selective estrogen receptor degrader for estrogen receptor–positive breast cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• INLURIYO (IMLUNESTRANT)

Snippet

ORIG AP for INLURIYO (IMLUNESTRANT)